Source Fact: Financial Supervisory Service DART / 2026-03-23
Disclosure Type: Submission of Audit Report
💡 3-Second Summary
Alteogen has officially received a clean ‘Unqualified’ audit opinion from Samil PwC for both its separate and consolidated financial statements. With its FY2025 consolidated operating profit officially locked in at KRW 106.9B, the company has completely eliminated any regulatory or delisting risks.
📊 1. [Key Disclosure Details & Figures Summary]
- External Auditor: Samil PricewaterhouseCoopers (Samil PwC)
- Audit Opinion: ‘Unqualified (Clean)’ for both Consolidated and Separate Financial Statements
- Going Concern Material Uncertainty: None (Financial sustainability securely verified)
- Confirmed Final Consolidated Financials (FY2025):
- Revenue: KRW 215,858,918,957 (Approx. KRW 215.9B / A massive 109.9% surge compared to KRW 102.9B in FY2024)
- Operating Profit: KRW 106,900,077,097 (Approx. KRW 106.9B / An explosive 320.8% jump compared to KRW 25.4B in FY2024)
- Net Profit: KRW 145,172,981,930 (Approx. KRW 145.2B)
- Capital Adequacy & Risk Metrics:
- Capital Impairment Ratio: N/A (Total equity stands at approx. KRW 454.4B against capital stock of KRW 26.8B)
- Consecutive Losses: None. The company has completely exited its historical loss cycle (FY2021-2023), zeroing out any possibility of being designated as an administrative issue.
📈 2. [Expert Insight: Stock Price Impact Analysis]
- Flawless Exit from Biotech’s Infamous ‘March Audit Panic’: While March is traditionally a high-risk season where many Korean biotech companies face trade suspensions due to qualified or adverse audit opinions, Alteogen has completely cleared its accounting risks with a top-tier auditor’s stamp. This acts as a powerful safety net that allows major domestic and foreign institutions to invest with confidence.
- Fundamental Transformation Backed by Validated Numbers: This report converts previous tentative numbers into legally certified financial facts. Achieving a certified consolidated operating profit of KRW 106.9B proves that Alteogen is no longer a speculative cash-burning biotech, but a highly structured, structurally profitable platform giant.
- Acceleration of Global Long-Only Institutional Inflows: With zero capital impairment and robust pretax income growth, Alteogen has cleared every potential pitfall on the Kosdaq regulatory checklist. This flawless institutional validation will significantly enhance its Fundamental appeal, paving the way for larger weights in global indices (such as MSCI) and continuous passive fund inflows.
📝 Editor’s Comment (by K-STOCK Editor)
Alteogen has demolished the notorious ‘Audit Report Phobia’ that haunts biotech investors every March in the most definitive way possible. The true significance of this disclosure extends beyond a simple compliance pass; it legally solidifies Alteogen’s entry into the elite hundred-billion-won operating profit club. The clean audit stamp from Samil PwC on the KRW 106.9B operating profit serves as ironclad legal proof that Alteogen’s platform technology licensing business model is a highly sustainable cash cow, not a one-time mirage. With all financial roadblocks completely eliminated, the undisputed sector leader is fully cleared for its next bullish run.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!